Ultragenyx Pharmaceutical Inc. Stock News

Favored companies include Uber, General Motors and Twilio.

ClearBridge Small Cap Strategy outperformed its Index benchmark during Q1. Who were the leading detractors and contributors? Click here to find out.

Ultragenyx is a leader in rare diseases, with 4 approved products and 6 pipeline programs.

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ: RARE ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 3 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Ultragenyx Pharmaceutical has an average price target of $118.75 with a high of $132.00 and a low of $105.00. Below is a summary of how these 4 analysts rated Ultragenyx Pharmaceutical over the past 3 months. The greater … Full story available on Benzinga.com

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to year-ago quarter EPS of

Ultragenyx Pharmaceutical (NASDAQ: RARE ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 3 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $118.75 versus the current price of Ultragenyx Pharmaceutical at $66.395, implying upside. Below is a summary of how these 4 analysts rated Ultragenyx Pharmaceutical over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the … Full story available on Benzinga.com

Credit Suisse has upgraded UltraGenyx to outperform from neutral citing the company''s potential risk/reward ahead of a program update on its Angelman Syndrome candidate.The firm also…

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024 WALTHAM, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ: TCRX ), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities. "As we had guided throughout 2021, in December we filed two INDs for our liquid tumor program. We also completed construction of our now fully functional 7,000 square-foot GMP manufacturing facility. Both of these steps are instrumental in our transformation to a clinical-stage company," said David Southwell, President and Chief Executive Officer. "We also advanced our growing pipeline of solid tumor candidates and look forward to sharing further details around these programs in the coming months." Recent Corporate Highlights In January 2022, the Company announced that the U.S.

NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for

NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 PM ET.

In last trading session, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw 0.35 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $67.45 trading at -$0.37 or -0.55% at ring of the bell on the day assigns it a market valuation of $4.72B. That closing price of RARE’s stock is … Analysts Predict Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) To Reach $186.00 In 12 Months Read More »

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.